查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471991

前列腺癌治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按治疗类型、最终用户和地理位置

Prostate Cancer Treatment Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End Users, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

摄护腺癌治疗市场预计将从2022年的190.7亿美元成长到2030年的341.1亿美元；预计2022年至2030年复合年增长率为7.5%。

前列腺癌是男性最常见的健康问题之一，尤其是老年男性（50岁以上）。在明显症状的情况下发展，因此，这种癌症的早期发现并不容易。对尿道施加压力，或在某些情况下，转移引起的骨痛可能是晚期前列腺癌的首发症状，但是，任何50 岁或以上出现下泌尿道症状、勃起功能障碍或血尿的个体都应考虑。摄护腺癌的可能性是全球男性癌症死亡的第五大原因，也是第二常见的癌症。

不断增加的策略性措施推动前列腺癌治疗市场的成长。

在前列腺癌治疗市场运营的小型和大型公司采取各种策略，例如地理扩张、新产品发布和技术进步来增加收入。以下提到了前列腺癌治疗市场的一些最新发展。

2023年11月，FDA批准了安斯泰来製药美国公司生产的恩杂鲁胺，用于治疗具有高转移风险的生化復发的非转移性去势敏感型前列腺癌（nmCSPC）（高风险BCR） ）。

2023年11月，安斯泰来製药公司收购了Propella Therapeutics Inc.和PRL-02（阿比特龙癸酸酯），PRL-02是Propella开发的用于治疗前列腺癌的下一代雄激素生物合成抑制剂。

2023年4月，FDA授予Lantheus Holdings Inc.和POINT Biopharma Global Inc. 177Lu-PNT2002治疗转移性去势抵抗性前列腺癌（mCRPC）的快速通道资格。 PNT2002是一种创新的PSMA靶向177Lu放射性药物疗法，结合了PSMA靶向配体、PSMA-I&T和β发射放射性同位素无载体177Lu，用于治疗mCRPC。

2023年6月，阿斯特捷利康和默沙东的Lynparza（olaparib）合併泼尼鬆或泼尼松龙和阿比特龙在美国被批准用于治疗疑似有害BRCA突变（BRCAm）转移性去势抵抗性前列腺癌（mCRPC）的成年患者。

2023 年2 月，Fusion Pharmaceuticals Inc. 宣布从RadioMedix, Inc.（「RadioMedix」）收购研究性新药申请（「IND」），用于正在进行的评估225Ac-PSMA 的2 期临床试验（「TATCIST」试验） I&T，一种针对前列腺癌上表达的前列腺特异性膜抗原（“PSMA”）的小分子。交易结束后，TATCIST 试验中正在评估的α发射放射性药物命名为 FPI-2265。

2022年3月，美国FDA核准诺华公司的Pluvicto（镥Lu 177 vipivotide tetraxetan）用于治疗晚期前列腺癌（称为前列腺特异性膜抗原阳性转移性去势抗性前列腺癌（PSMA阳性mCRPC） ）的成年患者。

市场参与者积极参与扩张、合作和併购，促进了前列腺癌治疗市场的成长。

前列腺癌治疗市场报告的范围涵盖北美（美国、加拿大和墨西哥）、欧洲（西班牙、英国、德国、法国、义大利和欧洲其他地区）、亚太地区（韩国、中国、印度、日本、澳洲和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地区）。北美是全球前列腺癌治疗市场成长的最大贡献者。预计 2022 年至 2030 年，亚太地区的前列腺癌治疗市场复合年增长率最高。美国前列腺癌治疗市场的成长主要是由前列腺癌发病率上升、产品发布和政府倡议推动的。公司推出的各种治疗前列腺癌的产品也促进了市场的成长。例如，2023年6月，阿斯特捷利康和默沙东的Lynparza（olaparib）合併泼尼鬆或泼尼松龙和阿比特龙在美国被批准用于治疗疑似有害BRCA突变（BRCAm）转移性去势抵抗性前列腺癌（mCRPC）的成年患者）。此外，2023年11月，FDA批准了Astellas Pharma US, Inc.生产的恩杂鲁胺（enzalutamide），用于治疗具有高转移风险（高风险）生化復发的非转移性去势敏感型前列腺癌（ nmCSPC）。

世界卫生组织 (WHO)、疾病管制与预防中心 (CDC) 以及食品药物管理局 (FDA) 是在准备前列腺癌治疗市场报告时提到的几个关键的主要和次要来源。

目录

第 1 章：简介

第 2 章：要点

第 3 章：研究方法

第 4 章：前列腺癌治疗市场格局

  • 概述
  • 害虫分析
    • 北美 - 害虫分析
    • 欧洲 - 害虫分析
    • 亚太地区 - 害虫分析
    • 中东和非洲 - 害虫分析
    • 南美洲和中美洲 - 害虫分析
  • 专家意见

第 5 章：前列腺癌治疗市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驾驶员和约束的影响分析

第 6 章：前列腺癌治疗市场 - 全球市场分析

  • 前列腺癌治疗 - 全球市场概览
  • 前列腺癌治疗 - 全球市场和到 2031 年的预测
  • 市场定位

第 7 章：前列腺癌治疗市场 - 收入和 2031 年预测 - 治疗类型

  • 概述
  • 治疗类型市场预测与分析
  • 荷尔蒙疗法
    • 概述
    • 荷尔蒙治疗市场预测与分析
  • 化疗
    • 概述
    • 化疗市场预测与分析
  • 免疫治疗
    • 概述
    • 免疫疗法市场预测与分析
  • 标靶治疗
    • 概述
    • 标靶治疗市场预测与分析
  • 手术
    • 概述
    • 手术市场预测与分析
  • 放射治疗
    • 概述
    • 放射治疗市场预测与分析

第 8 章：前列腺癌治疗市场 - 2031 年收入和预测 - 分销管道

  • 概述
  • 分销通路市场预测与分析
  • 医院
    • 概述
    • 医院市场预测与分析
  • 诊所
    • 概述
    • 诊所市场预测与分析
  • 其他的
    • 概述
    • 其他市场预测与分析

第 9 章：前列腺癌治疗市场收入和 2031 年预测 - 地理分析

  • 北美洲
    • 北美洲
    • 欧洲
    • 亚太
    • 中东和非洲
    • 南美洲和中美洲

第 11 章：产业格局

  • 併购
  • 协议、合作和合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：前列腺癌治疗市场，主要公司概况

  • JOHNSON AND JOHNSON
  • ASTELLA PHARMA INC.
  • SANOFI
  • DENDREON PHARMACEUTICALS LLC
  • CARDINAL HEALTH
  • ASTRAZENECA
  • BAYER AG
  • TOLMAR INC
  • ENDO PHARMACEUTICALS INC
  • ABBVIE, INC.

第 13 章：附录

简介目录
Product Code: TIPRE00021050

The prostate cancer treatment market is expected to grow from US$ 19.07 billion in 2022 to US$ 34.11 billion by 2030; it is anticipated to record a CAGR of 7.5% from 2022 to 2030.

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years. Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that is it often develops without noticeable symptoms and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra or in some cases bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Prostate cancer is the 5th leading cause of cancer death among men worldwide and the 2nd most commonly diagnosed cancer.

Increasing Strategic Initiatives Propels Prostate Cancer Treatment Market Growth.

Small and big companies operating in the prostate cancer therapeutics market adopt various strategies such as geographic expansion, new product launches, and technological advancements to boost their revenues. A few recent developments in the prostate cancer treatment market are mentioned below.

In November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc. which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

In November 2023, Astellas Pharma Inc. acquired Propella Therapeutics Inc. and PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor developed by Propella to treat prostate cancer.

In April 2023, the FDA granted Lantheus Holdings Inc. and POINT Biopharma Global Inc. fast track designation for 177Lu-PNT2002 to treat metastatic castration-resistant prostate cancer (mCRPC). PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines PSMA-targeted ligand, PSMA-I&T, and beta-emitting radioisotope no-carrier-added 177Lu for treating mCRPC.

In June 2023, AstraZeneca and MSD's Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US to treat the adult patients who suffer from suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

In February 2023, Fusion Pharmaceuticals Inc. announced the acquisition from RadioMedix, Inc. ("RadioMedix") of the investigational new drug application ("IND") for an ongoing Phase 2 clinical trial (the "TATCIST" trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial named as FPI-2265.

In March 2022, the US FDA approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treating adult patients with a type of advanced prostate cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).

The active participation of market players in expansions, partnerships, and mergers and acquisitions boosts the growth of the prostate cancer treatment market.

The scope of the prostate cancer treatment market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market during 2022-2030. The growth of the prostate cancer therapeutics market in the US is mainly driven by the increasing incidence of prostate cancer cases, product launches, and government initiatives. Various product launches for the treatment of prostate cancer by companies are also bolstering the market growth. For instance, in June 2023, AstraZeneca and MSD's Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US for the treatment of adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). In addition, in November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc. which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) are a few key primary and secondary sources referred to while preparing the report on the prostate cancer treatment market.

Table Of Contents

1. INTRODUCTION

  • 1.1. SCOPE OF THE STUDY
  • 1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
  • 1.3. MARKET SEGMENTATION
    • 1.3.1 Prostate Cancer Treatment Market - By Therapy Type
    • 1.3.2 Prostate Cancer Treatment Market - By Distribution Channel
    • 1.3.3 Prostate Cancer Treatment Market - By Region
      • 1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. PROSTATE CANCER TREATMENT MARKET LANDSCAPE

  • 4.1. OVERVIEW
  • 4.2. PEST ANALYSIS
    • 4.2.1 North America - Pest Analysis
    • 4.2.2 Europe - Pest Analysis
    • 4.2.3 Asia-Pacific - Pest Analysis
    • 4.2.4 Middle East and Africa - Pest Analysis
    • 4.2.5 South and Central America - Pest Analysis
  • 4.3. EXPERT OPINIONS

5. PROSTATE CANCER TREATMENT MARKET - KEY MARKET DYNAMICS

  • 5.1. KEY MARKET DRIVERS
  • 5.2. KEY MARKET RESTRAINTS
  • 5.3. KEY MARKET OPPORTUNITIES
  • 5.4. FUTURE TRENDS
  • 5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. PROSTATE CANCER TREATMENT MARKET - GLOBAL MARKET ANALYSIS

  • 6.1. PROSTATE CANCER TREATMENT - GLOBAL MARKET OVERVIEW
  • 6.2. PROSTATE CANCER TREATMENT - GLOBAL MARKET AND FORECAST TO 2031
  • 6.3. MARKET POSITIONING

7. PROSTATE CANCER TREATMENT MARKET - REVENUE AND FORECASTS TO 2031 - THERAPY TYPE

  • 7.1. OVERVIEW
  • 7.2. THERAPY TYPE MARKET FORECASTS AND ANALYSIS
  • 7.3. HORMONAL THERAPY
    • 7.3.1. Overview
    • 7.3.2. Hormonal Therapy Market Forecast and Analysis
  • 7.4. CHEMOTHERAPY
    • 7.4.1. Overview
    • 7.4.2. Chemotherapy Market Forecast and Analysis
  • 7.5. IMMUNOTHERAPY
    • 7.5.1. Overview
    • 7.5.2. Immunotherapy Market Forecast and Analysis
  • 7.6. TARGETED THERAPY
    • 7.6.1. Overview
    • 7.6.2. Targeted Therapy Market Forecast and Analysis
  • 7.7. SURGERY
    • 7.7.1. Overview
    • 7.7.2. Surgery Market Forecast and Analysis
  • 7.8. RADIATION THERAPY
    • 7.8.1. Overview
    • 7.8.2. Radiation Therapy Market Forecast and Analysis

8. PROSTATE CANCER TREATMENT MARKET - REVENUE AND FORECASTS TO 2031 - DISTRIBUTION CHANNEL

  • 8.1. OVERVIEW
  • 8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
  • 8.3. HOSPITALS
    • 8.3.1. Overview
    • 8.3.2. Hospitals Market Forecast and Analysis
  • 8.4. CLINICS
    • 8.4.1. Overview
    • 8.4.2. Clinics Market Forecast and Analysis
  • 8.5. OTHERS
    • 8.5.1. Overview
    • 8.5.2. Others Market Forecast and Analysis

9. PROSTATE CANCER TREATMENT MARKET REVENUE AND FORECASTS TO 2031 - GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1 North America Prostate Cancer Treatment Market Overview9.1.2 North America Prostate Cancer Treatment Market Forecasts and Analysis9.1.3 North America Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.1.4 North America Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.1.5 North America Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.1.5.1 United States Prostate Cancer Treatment Market
        • 9.1.5.1.1 United States Prostate Cancer Treatment Market by Therapy Type9.1.5.1.2 United States Prostate Cancer Treatment Market by Distribution Channel 9.1.5.2 Canada Prostate Cancer Treatment Market
        • 9.1.5.2.1 Canada Prostate Cancer Treatment Market by Therapy Type9.1.5.2.2 Canada Prostate Cancer Treatment Market by Distribution Channel 9.1.5.3 Mexico Prostate Cancer Treatment Market
        • 9.1.5.3.1 Mexico Prostate Cancer Treatment Market by Therapy Type9.1.5.3.2 Mexico Prostate Cancer Treatment Market by Distribution Channel 9.2. EUROPE
    • 9.2.1 Europe Prostate Cancer Treatment Market Overview9.2.2 Europe Prostate Cancer Treatment Market Forecasts and Analysis9.2.3 Europe Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.2.4 Europe Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.2.5 Europe Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.2.5.1 Germany Prostate Cancer Treatment Market
        • 9.2.5.1.1 Germany Prostate Cancer Treatment Market by Therapy Type9.2.5.1.2 Germany Prostate Cancer Treatment Market by Distribution Channel 9.2.5.2 France Prostate Cancer Treatment Market
        • 9.2.5.2.1 France Prostate Cancer Treatment Market by Therapy Type9.2.5.2.2 France Prostate Cancer Treatment Market by Distribution Channel 9.2.5.3 Italy Prostate Cancer Treatment Market
        • 9.2.5.3.1 Italy Prostate Cancer Treatment Market by Therapy Type9.2.5.3.2 Italy Prostate Cancer Treatment Market by Distribution Channel 9.2.5.4 Spain Prostate Cancer Treatment Market
        • 9.2.5.4.1 Spain Prostate Cancer Treatment Market by Therapy Type9.2.5.4.2 Spain Prostate Cancer Treatment Market by Distribution Channel 9.2.5.5 United Kingdom Prostate Cancer Treatment Market
        • 9.2.5.5.1 United Kingdom Prostate Cancer Treatment Market by Therapy Type9.2.5.5.2 United Kingdom Prostate Cancer Treatment Market by Distribution Channel 9.2.5.6 Rest of Europe Prostate Cancer Treatment Market
        • 9.2.5.6.1 Rest of Europe Prostate Cancer Treatment Market by Therapy Type9.2.5.6.2 Rest of Europe Prostate Cancer Treatment Market by Distribution Channel 9.3. ASIA-PACIFIC
    • 9.3.1 Asia-Pacific Prostate Cancer Treatment Market Overview9.3.2 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis9.3.3 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.3.4 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.3.5 Asia-Pacific Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.3.5.1 Australia Prostate Cancer Treatment Market
        • 9.3.5.1.1 Australia Prostate Cancer Treatment Market by Therapy Type9.3.5.1.2 Australia Prostate Cancer Treatment Market by Distribution Channel 9.3.5.2 China Prostate Cancer Treatment Market
        • 9.3.5.2.1 China Prostate Cancer Treatment Market by Therapy Type9.3.5.2.2 China Prostate Cancer Treatment Market by Distribution Channel 9.3.5.3 India Prostate Cancer Treatment Market
        • 9.3.5.3.1 India Prostate Cancer Treatment Market by Therapy Type9.3.5.3.2 India Prostate Cancer Treatment Market by Distribution Channel 9.3.5.4 Japan Prostate Cancer Treatment Market
        • 9.3.5.4.1 Japan Prostate Cancer Treatment Market by Therapy Type9.3.5.4.2 Japan Prostate Cancer Treatment Market by Distribution Channel 9.3.5.5 South Korea Prostate Cancer Treatment Market
        • 9.3.5.5.1 South Korea Prostate Cancer Treatment Market by Therapy Type9.3.5.5.2 South Korea Prostate Cancer Treatment Market by Distribution Channel 9.3.5.6 Rest of Asia-Pacific Prostate Cancer Treatment Market
        • 9.3.5.6.1 Rest of Asia-Pacific Prostate Cancer Treatment Market by Therapy Type9.3.5.6.2 Rest of Asia-Pacific Prostate Cancer Treatment Market by Distribution Channel 9.4. MIDDLE EAST AND AFRICA
    • 9.4.1 Middle East and Africa Prostate Cancer Treatment Market Overview9.4.2 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis9.4.3 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.4.4 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.4.5 Middle East and Africa Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.4.5.1 South Africa Prostate Cancer Treatment Market
        • 9.4.5.1.1 South Africa Prostate Cancer Treatment Market by Therapy Type9.4.5.1.2 South Africa Prostate Cancer Treatment Market by Distribution Channel 9.4.5.2 Saudi Arabia Prostate Cancer Treatment Market
        • 9.4.5.2.1 Saudi Arabia Prostate Cancer Treatment Market by Therapy Type9.4.5.2.2 Saudi Arabia Prostate Cancer Treatment Market by Distribution Channel 9.4.5.3 U.A.E Prostate Cancer Treatment Market
        • 9.4.5.3.1 U.A.E Prostate Cancer Treatment Market by Therapy Type9.4.5.3.2 U.A.E Prostate Cancer Treatment Market by Distribution Channel 9.4.5.4 Rest of Middle East and Africa Prostate Cancer Treatment Market
        • 9.4.5.4.1 Rest of Middle East and Africa Prostate Cancer Treatment Market by Therapy Type9.4.5.4.2 Rest of Middle East and Africa Prostate Cancer Treatment Market by Distribution Channel 9.5. SOUTH AND CENTRAL AMERICA
    • 9.5.1 South and Central America Prostate Cancer Treatment Market Overview9.5.2 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis9.5.3 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis - By Therapy Type9.5.4 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis - By Distribution Channel9.5.5 South and Central America Prostate Cancer Treatment Market Forecasts and Analysis - By Countries 9.5.5.1 Brazil Prostate Cancer Treatment Market
        • 9.5.5.1.1 Brazil Prostate Cancer Treatment Market by Therapy Type9.5.5.1.2 Brazil Prostate Cancer Treatment Market by Distribution Channel 9.5.5.2 Argentina Prostate Cancer Treatment Market
        • 9.5.5.2.1 Argentina Prostate Cancer Treatment Market by Therapy Type9.5.5.2.2 Argentina Prostate Cancer Treatment Market by Distribution Channel 9.5.5.3 Rest of South and Central America Prostate Cancer Treatment Market
        • 9.5.5.3.1 Rest of South and Central America Prostate Cancer Treatment Market by Therapy Type9.5.5.3.2 Rest of South and Central America Prostate Cancer Treatment Market by Distribution Channel10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PROSTATE CANCER TREATMENT MARKET
  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 Middle East and Africa
  • 10.5 South and Central America

11. INDUSTRY LANDSCAPE

  • 11.1. MERGERS AND ACQUISITIONS
  • 11.2. AGREEMENTS, COLLABORATIONS AND JOINT VENTURES
  • 11.3. NEW PRODUCT LAUNCHES
  • 11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. PROSTATE CANCER TREATMENT MARKET, KEY COMPANY PROFILES

  • 12.1. JOHNSON AND JOHNSON
    • 12.1.1. Key Facts
    • 12.1.2. Business Description
    • 12.1.3. Products and Services
    • 12.1.4. Financial Overview
    • 12.1.5. SWOT Analysis
    • 12.1.6. Key Developments
  • 12.2. ASTELLA PHARMA INC.
    • 12.2.1. Key Facts
    • 12.2.2. Business Description
    • 12.2.3. Products and Services
    • 12.2.4. Financial Overview
    • 12.2.5. SWOT Analysis
    • 12.2.6. Key Developments
  • 12.3. SANOFI
    • 12.3.1. Key Facts
    • 12.3.2. Business Description
    • 12.3.3. Products and Services
    • 12.3.4. Financial Overview
    • 12.3.5. SWOT Analysis
    • 12.3.6. Key Developments
  • 12.4. DENDREON PHARMACEUTICALS LLC
    • 12.4.1. Key Facts
    • 12.4.2. Business Description
    • 12.4.3. Products and Services
    • 12.4.4. Financial Overview
    • 12.4.5. SWOT Analysis
    • 12.4.6. Key Developments
  • 12.5. CARDINAL HEALTH
    • 12.5.1. Key Facts
    • 12.5.2. Business Description
    • 12.5.3. Products and Services
    • 12.5.4. Financial Overview
    • 12.5.5. SWOT Analysis
    • 12.5.6. Key Developments
  • 12.6. ASTRAZENECA
    • 12.6.1. Key Facts
    • 12.6.2. Business Description
    • 12.6.3. Products and Services
    • 12.6.4. Financial Overview
    • 12.6.5. SWOT Analysis
    • 12.6.6. Key Developments
  • 12.7. BAYER AG
    • 12.7.1. Key Facts
    • 12.7.2. Business Description
    • 12.7.3. Products and Services
    • 12.7.4. Financial Overview
    • 12.7.5. SWOT Analysis
    • 12.7.6. Key Developments
  • 12.8. TOLMAR INC
    • 12.8.1. Key Facts
    • 12.8.2. Business Description
    • 12.8.3. Products and Services
    • 12.8.4. Financial Overview
    • 12.8.5. SWOT Analysis
    • 12.8.6. Key Developments
  • 12.9. ENDO PHARMACEUTICALS INC
    • 12.9.1. Key Facts
    • 12.9.2. Business Description
    • 12.9.3. Products and Services
    • 12.9.4. Financial Overview
    • 12.9.5. SWOT Analysis
    • 12.9.6. Key Developments
  • 12.10. ABBVIE, INC.
    • 12.10.1. Key Facts
    • 12.10.2. Business Description
    • 12.10.3. Products and Services
    • 12.10.4. Financial Overview
    • 12.10.5. SWOT Analysis
    • 12.10.6. Key Developments

13. APPENDIX

  • 13.1. ABOUT THE INSIGHT PARTNERS
  • 13.2. GLOSSARY OF TERMS